Pregnancy and infant outcomes following abatacept exposure during pregnancy
Clicks: 5
ID: 321651
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
1.2
/100
5 views
2 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #26 of 46 articles by views in Rheumatology Advances in Practice
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Objectives Abatacept is approved for the treatment of moderate to severe rheumatoid arthritis, juvenile idiopathic arthritis, and psoriatic arthritis in the U.S. and elsewhere. The purpose of this study was to estimate the incidence/birth prevalence of selected maternal and infant outcomes in pregnancies exposed to abatacept. Methods Pregnant women exposed to any dose of abatacept from the first day of the last menstrual period to the end of the first trimester who resided in the U.S. or Canada were enrolled in the Organization of Teratology Information Specialists Abatacept Pregnancy Exposure Registry between 2007 and 2019. Data on exposures, outcomes, and covariates were collected by maternal interviews, medical records, and study-related physical examinations up to one year postpartum. Results The sample consisted of 30 abatacept-exposed pregnancies. Sixteen were enrolled prospectively and were treated for rheumatoid arthritis or psoriatic arthritis; 14 did not meet the prospective criteria and were enrolled in an exposure series. Of those prospectively enrolled, 2/13 (15.4%) involved an infant with a major birth defect, 2/16 (12.5%) ended in spontaneous abortion, and 2/13 (15.4%) delivered preterm. In the exposure series, 5/14 livebirths (35.7%) ended with an infant with a major birth defect, two of which were chromosomal or genetic, and 6/14 (42.9%) delivered preterm. Conclusion There were no patterns of major or minor birth defects identified in either group. In the exposure series, selected adverse outcomes were more frequent; likely due to biases that led to exclusion of these pregnancies from the prospective cohort.
| Reference Key |
openalex_W7169758426
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Christina Chambers, Michelle Ann Caesar, Diana L. Johnson, Ronghui Xu, Yunjun Luo, Stephen R. Braddock, Margaret P Adam, Luther K. Robinson, K L Jones, C Stallman, B Maloney, K Perrotta, A Messer, S Voyer Lavigne, C Senechal, E A Conover, J L Poskochil, P Cole, L Harris-Sagaribay, C Haldeman-Englert, R Muller, N Krstic, R Miller, L Wolfe, S Sherman, K Richardson, M Ashfaq, M Leen-Mitchell, J Carey, C Coles, H Hazard |
| Journal | Rheumatology Advances in Practice |
| Year | 2026 |
| DOI |
10.1093/rap/rkag084
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.